Monday, October 26, 2026

Fixed Income Trading

2 articles

30-Year Treasury Yields Breach 5% as Bond Markets Flash Global Fiscal Warning

30-Year Treasury Yields Breach 5% as Bond Markets Flash Global Fiscal Warning

30-year U.S. Treasury yields have broken above 5% and UK gilt yields have hit their highest levels since the 1990s, signaling a synchronized global bond market selloff. Persistent inflation driven by the Iran conflict and tariff uncertainty—compounding $857 in added annual gasoline costs for American households—is colliding with record sovereign debt loads and an impending Fed leadership transition. Diplomatic progress from the Trump-Xi summit and U.S.-China tariff reductions provides partial re

LM Salvado•
Treasury 30-Year Yields Cross 5%, UK Gilts Hit 1990s Highs — The Bond Revolt Traders Must Watch

Treasury 30-Year Yields Cross 5%, UK Gilts Hit 1990s Highs — The Bond Revolt Traders Must Watch

30-year Treasury yields have crossed 5% and UK gilts are trading at levels last seen in the 1990s, signaling a structural inflation regime rather than a cyclical episode. CPI holds at 3.8% with services inflation above 3% annually, compounded by the Iran war adding $857 to Americans' average gasoline costs in 2026. Jerome Powell's departure has created a Fed leadership vacuum that amplifies market uncertainty at the worst possible moment.

LM Salvado•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com